Chikungunya Vaccine Development May Rely On Immunologic Biomarkers Instead Of Traditional Trials
As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.
You may also be interested in...
Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines
US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.
Epidemiology complicates field efficacy trials, but US FDA advisory committee members regretfully agree that data from non-human primate passive transfer studies is compelling but potentially insufficient for chikungunya vaccines.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.